← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Intervexion Therapeutics, Llc
Little Rock, AR
$71,667,060
Total funding
9
Grants
Funding over time
peak $11.5M · FY2005–24$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$71,667,060 · 9
By mechanism
U01$64,553,944 · 7
RC2$3,964,137 · 1
R42$3,148,979 · 1
Investigators at Intervexion Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,609,902
U01 · FY2023 · DA
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$4,601,742
U01 · FY2017 · DA
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,597,509
U01 · FY2021 · DA
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,570,609
U01 · FY2022 · DA
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder$4,336,347
U01 · FY2023 · DA
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder$4,314,989
U01 · FY2024 · DA
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND$4,033,814
U01 · FY2016 · DA
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$3,750,210
U01 · FY2021 · DA
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND$3,606,802
U01 · FY2014 · DA
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$3,165,675
U01 · FY2021 · DA
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$3,136,427
U01 · FY2020 · DA
Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity$2,769,478
RC2 · FY2010 · DA
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$2,735,856
U01 · FY2018 · DA
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$2,492,018
U01 · FY2020 · DA
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$2,115,968
U01 · FY2022 · DA
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$2,085,133
U01 · FY2016 · DA
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$1,863,102
U01 · FY2022 · DA
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND$1,843,400
U01 · FY2015 · DA
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$1,594,873
U01 · FY2015 · DA
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$1,429,307
U01 · FY2019 · DA